Basic Information
Jinarc
Regulatory Information
EMEA/H/C/002788
May 27, 2015
February 26, 2015
23
November 20, 2024
Company Information
Netherlands
Herikerbergweg 292 1101 CT Amsterdam
Otsuka Pharmaceutical Netherlands B.V.
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.
Overview Summary
Jinarc is a medicine used to treat adults with autosomal dominant polycystic kidney disease. This is an inherited condition in which numerous fluid-filled cysts develop in the kidneys, which eventually affect kidney function and can cause the kidneys to fail. Jinarc is for use in patients with normal to moderately reduced kidney function at the beginning of treatment with Jinarc and whose disease is progressing rapidly. Jinarc contains the active substance tolvaptan.